Anzeige
Erschienen in:
01.10.2011 | Original Article
Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin
Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2011
Einloggen, um Zugang zu erhaltenAbstract
Background
The response to pegylated interferon (peg-IFN) plus ribavirin therapy remains less than ideal with 40–50% of treated subjects failing to clear the virus. Moreover, retreatment is only minimally effective. Consensus interferon (c-IFN) has been shown to be efficacious in HCV genotype 1 patients who have failed therapy with peg-IFN.
Aim
To evaluated the response to re-treatment of peg-IFN plus ribavirin partial-responders with c-IFN plus ribavirin.
Methods
Forty-two subjects who had previously failed to clear virus after treatment with peg-IFN plus ribavirin were treated with c-IFN (15 μg/day) plus ribavirin (800–1,200 mg/day) until 12 months of therapy or a total of six consecutive months of PCR negativity was achieved.
Results
The study population consisted predominantly of males (71%), Caucasians (76%), with African Americans comprising the remaining 24%, subjects with HCV genotype 1 infection (81%) and 21% had cirrhosis by liver biopsy. The overall SVR rate was 29%. The only pretreatment variable that distinguished responders from partial-responders was the serum triglyceride level.
Conclusions
The use of c-IFN plus ribavirin in the retreatment of prior peg-IFN plus ribavirin partial responders is essentially twice that achieved in prior re-treatment regimens consisting of a second course of peg-IFN plus ribavirin. These results will need to be evaluated against the use of triple therapy consisting of a peg-IFN plus ribavirin and a protease inhibitor. More studies utilizing c-IFN plus ribavirin with either a protease inhibitor or polymerase inhibitor need to be performed as well.